Literature DB >> 33564285

Simultaneous microRNA-612 restoration and 5-FU treatment inhibit the growth and migration of human PANC-1 pancreatic cancer cells.

Darya Javadrashid1,2, Reza Mohammadzadeh2, Amir Baghbanzadeh1, Sahar Safaee1, Mohammad Amini1, Ziba Lotfi1, Elham Baghbani1, Vahid Khaze Shahgoli1, Behzad Baradaran1.   

Abstract

Despite the recent advances in the treatment of other cancers, the 5-year survival rate of pancreatic cancer remains under 9 %. Chemotherapy and surgical resection are the most common therapy methods. The regulatory role of microRNAs in different types of cancer has given them therapeutic importance. miR-612 has been downregulated in colorectal, bladder, liver, and some other types of cancer and could be considered a tumor-suppressor miRNA. 5-FU is one of the most common chemotherapeutic agents used in pancreatic cancer treatment, which is used in multiple drug regimens and combinatorial therapy methods. The aim of this study is the evaluation of miR-612 restoration in the PANC-1 cell line and using the tumor-suppressive effect of it in combination with 5-FU on cell growth and migration. MiR-612 mimic was transfected to PANC-1 cells through electroporation. Following the transfection, expression levels of miR-612 and BAX, BCL-2, Caspase-3, MMP9, and PD-L1 genes were measured by qRT-PCR. MTT assay was used to determine the cytotoxicity of miR-612 and 5-FU on PANC-1 cell viability. To confirm MTT results and to evaluate the quantitative effect of apoptosis induction flow cytometry test was used and in order to confirm apoptosis test results and cell cycle arrest evaluation DAPI staining and cell, cycle tests were conducted, respectively. Finally, to assess the inhibitory effect of miR-612 in combination with 5-FU on migration and growth wound healing and colony formation assays were used, respectively. Results demonstrated that miR-612 alongside 5-FU has an important role in the inhibition of migration and growth and also apoptosis induction in PANC-1 cells and could be considered as a supporting agent of chemotherapy and a novel therapeutic modality in pancreatic cancer treatment.
Copyright © 2021 Javadrashid et al.

Entities:  

Keywords:  5-FU; PANC-1; electroporation; miR-612; pancreatic cancer

Year:  2021        PMID: 33564285      PMCID: PMC7868639          DOI: 10.17179/excli2020-2900

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


  3 in total

Review 1.  Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer.

Authors:  Yi Ding; Zehua Wang; Fengmei Zhou; Chen Chen; Yanru Qin
Journal:  Front Oncol       Date:  2022-09-30       Impact factor: 5.738

Review 2.  Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review).

Authors:  Xiaoran Ma; Jibiao Wu; Bin Wang; Cun Liu; Lijuan Liu; Changgang Sun
Journal:  Int J Oncol       Date:  2022-09-21       Impact factor: 5.884

3.  Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine.

Authors:  Afshin Derakhshani; Shahryar Hashemzadeh; Zahra Asadzadeh; Mahdi Abdoli Shadbad; Farnaz Rasibonab; Hossein Safarpour; Vahid Jafarlou; Antonio Giovanni Solimando; Vito Racanelli; Pankaj Kumar Singh; Souzan Najafi; Darya Javadrashid; Oronzo Brunetti; Nicola Silvestris; Behzad Baradaran
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.